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Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer. The purpose of this study is to
define a biological pathway signature and a cellular differentiation program in ccRCC.
Methodology: We performed gene expression profiling of early-stage ccRCC and patient-matched normal renal tissue using
Affymetrix HG-U133a and HG-U133b GeneChips combined with a comprehensive bioinformatic analyses, including pathway
analysis. The results were validated by real time PCR and IHC on two independent sample sets. Cellular differentiation
experiments were performed on ccRCC cell lines and their matched normal renal epithelial cells, in differentiation media, to
determine their mesenchymal differentiation potential.
Principal Findings: We identified a unique pathway signature with three major biological alterations—loss of normal renal
function, down-regulated metabolism, and immune activation–which revealed an adipogenic gene expression signature
linked to the hallmark lipid-laden clear cell morphology of ccRCC. Culturing normal renal and ccRCC cells in differentiation
media showed that only ccRCC cells were induced to undergo adipogenic and, surprisingly, osteogenic differentiation. A
gene expression signature consistent with epithelial mesenchymal transition (EMT) was identified for ccRCC. We revealed
significant down-regulation of four developmental transcription factors (GATA3, TFCP2L1, TFAP2B, DMRT2) that are
important for normal renal development.
Conclusions: ccRCC is characterized by a lack of epithelial differentiation, mesenchymal/adipogenic transdifferentiation, and
pluripotent mesenchymal stem cell-like differentiation capacity in vitro. We suggest that down-regulation of developmental
transcription factors may mediate the aberrant differentiation in ccRCC. We propose a model in which normal renal
epithelial cells undergo dedifferentiation, EMT, and adipogenic transdifferentiation, resulting in ccRCC. Because ccRCC cells
grown in adipogenic media regain the characteristic ccRCC phenotype, we have indentified a new in vitro ccRCC cell model
more resembling ccRCC tumor morphology.
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Introduction
Renal cell carcinoma is the eighth most common cancer and
highly lethal, accounting for about 13,000 deaths in the U.S. in
2009 [1]. If detected in early stages, it is potentially curable by
surgical resection; however, there is no curative treatment for
metastatic RCC. A better understanding of RCC’s biology is
essential to improving prognosis.
ccRCC represents the most common subtype (83%) of RCC
[2]. The cell of origin and cellular differentiation program in
ccRCC is not definitively known but ccRCC is commonly thought
to arise from renal proximal epithelial cells [3]. The most striking
phenotypic feature of ccRCC is its clear cell morphology, which
has been linked to lipid and glycogen accumulation [4]. Thus the
mechanism behind clear cell morphology is an important
component of renal carcinogenesis that has yet to be defined at
the molecular level.
The gene expression profile of ccRCC has been investigated at
the single gene level in multiple studies [5];[6] that have compared
ccRCC to normal renal samples and other histological subtypes of
RCC. Many statistically significant individual genes have been
identified. At present, no comprehensive analysis of ccRCC at the
pathway level exists. Since biological processes are mediated by
multiple genes working in synchrony and genes are co-regulated,
pathway analysis is more conclusive regarding biologic changes.
Notably, genes that don’t seem differentially expressed at a
statistically significant level may reveal biologically significant
changes when studied in ontology groups [7]. Moreover, a
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number of differentially expressed genes, which makes biological
interpretation difficult. As a result, we conclude it is important to
study gene expression profiles comprehensively by grouping
individual genes into gene sets or pathways to extract more
sophisticated biological interpretations.
We used SigPathway [8], a genome-wide biological pathway
analysis package, and discovered three major biologic alterations
in early-stage ccRCC that are likely related to a loss of epithelial
differentiation. Our findings revealed four known renal develop-
mental transcription factors (DTFs) that were significantly down-
regulated in ccRCC and likely related to the differentiation
changes in renal carcinogenesis. Further analysis revealed a novel
molecular signature consistent with adipogenic transdifferentia-
tion. This adipogenic molecular signature can explain the ‘‘clear
cell’’ RCC morphology noted by cytoplasmic lipid accumulation.
We also revealed a gene expression signature consistent with EMT
in ccRCC. Based on these findings, we propose a carcinogenic
cellular differentiation model of normal renal epithelial cells
(NREs) that includes dedifferentiation, EMT, and adipogenic
transdifferentiation that results in ccRCC.
Results
Pathway Signature of ccRCC with three major biological
alterations
SigPathway analysis of our gene expression data was performed
to identify a pathway signature of ccRCC. The top 40
differentially expressed pathways in ccRCC are listed in
Table 1. Three biological themes are identified in the pathway
signature of ccRCC, that include (1) loss of normal renal function,
(2) down-regulation of metabolism, and (3) activated immune
pathways.
All pathways related to normal renal function are down-
regulated and include excretion, sodium ion transport, sodium ion
binding, hydrogen transport, proton transport, chloride transport,
and voltage-gated potassium channel activity. The excretion
pathway is the most significant differentially expressed pathway
in ccRCC in terms of overall rank, indicating that loss of normal
renal function is the most striking biologic alteration. Other
identified pathways are related to ion and electrolyte transport.
Our heatmap presents the most noteworthy differentially ex-
pressed genes from these pathways (Fig. 1a).
The metabolic pathways are predominantly down-regulated
and can be classified into 4 groups. (1) The lipid metabolic
pathways are at the top of the list and include butanoate
metabolism, propanoate metabolism, fatty acid metabolism and
benzoate degradation via CoA ligation. (2) Energy metabolic
pathways include oxidoreductase activity which acts on CH-OH
group of donors, oxidoreductase activity which acts on the CH-
OH group of donors, NAD or NADP as acceptor, cellular
respiration, oxidoreductase activity, acting on the aldehyde or
oxo group of donors, group transfer coenzyme metabolism,
oxidative phosphorylation, oxidoreductase activity which acts on
the CH-CH group of donors, ATP synthesis, nucleoside
phosphate metabolism, and mitochondrial inner membrane. (3)
Protein and amino acid metabolic pathways include valine,
leucine, and isoleucine degradation, valine degradation, nitrogen
compound catabolism, amine catabolism, amino acid catabolism
and amino acid biosynthesis. (4) Carbohydrate metabolic
pathways include fructose and mannose metabolism and pentose
phosphate pathway. We have included the most differentially
expressed metabolic genes from these pathways in a heatmap
(Fig. 1b).
The immune pathways are significantly upregulated and
include response to virus, antigen processing, antigen presentation,
antigen presentation of endogenous antigen, regulation of cell
activation, antigen processing related to endogenous antigen via
MHC class I, and the regulation of lymphocyte activation. We
present a heatmap generated by cluster analysis of the immune
genes with significant alterations (Fig. 1c).
Validation studies
Validation at messenger RNA levels was performed by qPCR
on several selected genes from the three pathway categories
(Fig. 2a) and is consistent with the microarray data. IHC
validation of the most significant genes in the three pathway
categories was consistent with microarray and qPCR data,
compared to patient-matched renal tissues samples (Fig. 2b, 2c,
2d). This includes the decreased expression of kininogen 1
(KNG1, NM_000893), aquaporin 2 (AQP2, AW015506), and
sodium channel nonvoltage-gated 1b (SCNN1B, NM_000336) in
normal renal function (blue arrows: Fig. 2a and 2b). Increased
expression of enolase c (ENO2, NM_001975) and cytochrome
P450-family 2-subfamily J-polypeptide 2 (CYP2J2, NM_000775),
and decreased expression of Fructose-1,6-bisphosphate aldolase
(ALDOB, BF195998) were identified as part of the metabolic
alterations (green arrows: Fig. 2a and 2c). Increased expression
was observed in toll-like receptor 2 (TLR2, NM_003264) and C-
X-C chemokine receptor type 4 (CXCR4, AJ224869), which
relates to immune function (red arrows: Fig. 2a and 2d).
Validations of altered expressions of KNG1, SCNN1B, ALDOB,
and TLR2 are novel and are reported for the first time in ccRCC.
ccRCC is characterized by a loss of renal developmental
transcription factors
The pathway signature showed that ccRCC cells are quite
different from normal renal cells, the bulk of which are epithelial
cells. This indicates a loss of epithelial differentiation in ccRCC
because the top-rated biological alteration is a down-regulation of
pathways that are related to normal renal epithelial function. A
lack of tubular architecture in ccRCC histology also suggests a loss
of epithelial differentiation. We performed a comprehensive
analysis to identify significant gene alterations in transcription
factors that are known to be important for kidney development
and cellular differentiation. We first identified all transcriptional
factors in our dataset by using Gene Ontology gene set on
transcription (GO: 006350). Statistical analysis with ANOVA was
performed to derive a list of significantly altered transcription
factors in ccRCC compared to normal renal samples. We then
queried the literature for those transcription factors known to
regulate renal development and differentiation. Four renal
developmental transcription factors—GATA binding protein 3
(GATA3, AI796169), Transcription factor CP2-like 1 (TFCP2L1,
AW195353), transcription factor activating protein -2b (TFAP2B,
NM_003221) and Doublesex - mab-3 related transcription factor 2
(DMRT2, AF284225)—were significantly down-regulated in
ccRCC (Fig. S1) and validated in another independent data set
by qPCR consisting of 15 patient-matched normal renal and
ccRCC tissues (Fig. 2a: yellow arrows). This data is illustrated by
a heatmap and a table that outlines these transcription factors’
roles in renal development and show statistically significant P
values for down-regulation in ccRCC (Fig. 3a). Decreased
expression of TFCP2L1, TFAP2B, and DMRT2 were also
validated by IHC (Fig. 3b). Decreased GATA3 mRNA and
protein expression has also been confirmed in a recent publication
from our laboratory [9].
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Overall Rank Gene Set Category Pathway Set Size % Up NTk Rank NEk Rank
Pathways related to normal renal function
1 GO:0007588 excretion 40 2 3 4
7 GO:0006814 sodium ion transport 59 12 10 15
8 GO:0031402 sodium ion binding 53 11 12 21
28 GO:0006821 chloride transport 25 20 104 5
40 GO:0005249 voltage-gated potassium channel activity 38 42 354 24
22 GO:0006818 hydrogen transport 56 7 18 69
26 GO:0015992 proton transport 55 7 21 79
Metabolic pathways
16 GO:0051258 protein polymerization 33 79 56 8
27 GO:0016830 carbon-carbon lyase activity 28 29 102 1
Lipid metabolic pathways
2 KEGG Butanoate_metabolism 49 2 1 10
4 KEGG Propanoate_metabolism 42 5 6 16
15 KEGG Fatty_acid_metabolism 69 6 11 53
32 KEGG Benzoate_degradation_via_CoA_ligation 63 30 122 7
Energy metabolic pathways
5 GO:0016614 oxidoreductase activity, acting on CH-OH group of donors 83 16 9 13
6 GO:0016616 oxidoreductase activity, acting on the CH-CH group of donors,
NAD or NADP as acceptor
75 13 8 17
10 GO:0045333 cellular respiration 34 6 19 25
12 GO:0016903 oxidoreductase activity, acting on the aldehyde or oxo group of donors 31 19 50 2
18 GO:0006752 group transfer coenzyme metabolism 59 8 15 56
21 GO:0006119 oxidative phosphorylation 72 1 2 77
23 GO:0016627 oxidoreductase activity, acting on the CH-CH group of donors 34 21 68 19
25 KEGG ATP_synthesis 44 5 23 73
29 GO:0006753 nucleoside phosphate metabolism 43 2 25 96
31 GO:0005743 mitochondrial inner membrane 70 7 14 109
Protein and amino acid metabolic pathways
3 KEGG Valine,_leucine_and_isoleucine_degradation 55 7 4 9
24 BioCyc valine degradation I 21 14 86 3
33 GO:0044270 nitrogen compound catabolism 55 11 16 122
34 GO:0009310 amine catabolism 53 11 24 136
35 GO:0009063 amino acid catabolism 52 10 22 139
37 GO:0008652 amino acid biosynthesis 34 38 247 12
Carbohydrate metabolic pathways
36 KEGG Fructose_and_mannose_metabolism 48 38 187.5 6
38 KEGG Pentose_phosphate_pathway 25 40 247 22
Immune pathways
9 GO:0009615 response to virus 43 86 17 18
11 GO:0030333 antigen processing 42 98 5 44
13 GO:0019882 antigen presentation 46 89 7 50
14 GO:0019883 antigen presentation, endogenous antigen 25 100 13 47
17 GO:0050865 regulation of cell activation 22 86 48 20
19 GO:0019885 antigen processing, endogenous antigen via MHC class I 25 100 20 52
20 GO:0051249 regulation of lymphocyte activation 20 85 64 14
Other pathways
30 GO:0003690 double-stranded DNA binding 25 76 110 11
39 GO:0003777 microtubule motor activity 33 39 316 23
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regulated transcription factor in ccRCC. Using genes known to be
regulated by TFCP2L1 from another study that uses a transgenic
mouse model [10], we identified TFCP2L1-regulated genes in our
microarray dataset (Fig. 3c). These genes, which mediate
epithelial cell development and tubule formation, were present
in the normal renal function-related pathways and were down-
regulated in ccRCC tissues. It is likely that a loss of TFCP2L1 in
ccRCC plays a role in the loss of epithelial differentiation and
function in ccRCC.
ccRCC is characterized by adipogenic transdifferentiation
Since kidneys are mesenchymal in embryonic origin and
ccRCC tissues express mesenchymal markers such as vimentin
and fibronectin [11], we hypothesized that ccRCC cells have
Top differentially expressed pathways between early-stage ccRCC and matched normal renal tissues by SigPathway are shown. The pathway signature is characterized
by three major biological alterations: downregulation of pathways related to normal renal function, downregulation of metabolic pathways, and immune pathway
activation. NTK is a measure of the degree to which a given pathway differs from the other pathways. NEK is a measure of the degree to which the pathway composite
expression differs among phenotypes.
doi:10.1371/journal.pone.0010696.t001
Table 1. Cont.
Figure 1. Heatmap signature of clear cell renal cell carcinoma. a. Normal renal function-related pathway gene expression signature. b.
Metabolic pathway gene expression signature. c. Immune pathway gene expression signature. Upregulation of genes is indicated in red,
downregulation is indicated in green, and a similar expression is indicated in black, as generated by Cluster 3.0.
doi:10.1371/journal.pone.0010696.g001
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Because we know that ccRCC cells are ladened with lipids [4]
and that they histologically resemble adipocytes, we further
hypothesized that our ccRCC cells may have under-
gone adipogenic transdifferentiation, a type of mesenchymal
differentiation.
We confirmed lipid accumulation by IHC using oil Red ‘O’ stain
(Fig. 4b) and we identified a gene expression signature in ccRCC
that is consistent with adipogenic differentiation (Fig. 4a). The 22
genes used for the hierarchical cluster analysis came from the
adipogenesis human pathway [12] and literature review [13].
Peroxisomeproliferator-activatedreceptorc(PPARc,NM_015869)
and CCAAT/enhancer binding protein b (CEBPb, AL564683) are
transcription factors known to be required for adipogenesis and are
upregulated in ccRCC. PPARa (BC004162), known to promote
lipid degradation and b-oxidation of fatty acids, was downregulated
[14];[15];[16]. Adipose differentiation-related protein (ADFP,
BC005127), which is a marker of adipocyte differentiation and
lipid storage[5],wassignificantlyupregulatedandvalidatedbyIHC
(Fig. 4b). This upregulation of ADFP at the mRNA and protein
level in ccRCC cells, is consistent with published data [5].
Angiopoietin-like 4 (ANGPTL4, NM_016109), which increases
triglycerides by potent inhibition of lipoprotein lipase [17], was
increased in ccRCC tumor tissue by 23-fold and may play a major
role in lipid accumulation. Further, ANGPTL4 is upregulated
during adipocyte differentiation [18]. Stearoyl-CoA desaturase
(SCD, AB032261), which is involved in lipogenesis [19], was also
upregulated. GATA2 (AL563460) and GATA3, both known to
inhibitadipocytedifferentiation[20];[21],weredown-regulatedand
both were validated by IHC (Fig. 4b and [9]). Caveolin-1 (CAV1,
NM_001753), which has been linked to lipid droplet biology and
neutral lipid storage [22];[23], was significantly upregulated. Fatty
acid binding proteins (FABPs) are significantly altered in their
expression in ccRCC; FABP5 & 7 (NM_001444 & NM_001446)
were upregulated, while FABP1 & 3 (NM_001443 & AI041520)
were down-regulated. This pattern of directional alterations of
adipogenic gene expression in ccRCC is consistent with adipogenic
transdifferentiation. We further validated our findings by compar-
ing data from a publicly available gene expression database
(GSE#15641, deposited at Gene Expression Omnibus) of early-
stage ccRCCagainst normalrenal samples(Fig.S2). Thus,wehave
discovered a novel adipogenic signature in ccRCC.
ccRCC cells undergo induced adipogenic and osteogenic
transdifferentiation
Using our newly discovered adipogenic ccRCC signature, we
performed differentiation experiments on three human ccRCC cell
lines to test the adipogenic differentiation capacity of ccRCC in
adipogenic media. All ccRCC tumor cells grown in adipogenic
media underwent adipogenic transdifferentiation as revealed by oil
red ‘O’ staining for lipid droplets (Fig. 5a, 5b). Glycogen
accumulation was also observed through the use of Periodic Acid
Schiff-Hematoxylin (PASH) stain in adipogenic ccRCC tumor cells
(Fig. 5c). This transdifferentiation is unique to ccRCC because
adipogenic changes were not seen in controls (tumor cells in renal
media, MDCK and patient-matched normal renal epithelial cells in
both medias, Fig. 5). After this discovery, we performed osteogenic
transdifferentiation experiments on the four cell lines to determine
whether or not ccRCC cells were capable of other types of
mesenchymal differentiation. Surprisingly, osteogenic differentia-
tion, as verified by Alizarin stain, was observed in ccRCC cells
grown in osteogenic media, but not in any of the controls (Fig. 6).
ccRCC is characterized by EMT molecular markers
Genomic profiling identified known molecular markers of EMT
[24]. Utilizing data bases and the literature searches we compiled a
Figure 2. Validation of gene expression findings in clear cell renal cell carcinoma. a. Heatmap generated with qPCR data of DTFs and
various genes related to three biological alterations. Upregulation of genes is indicated in red, downregulation is indicated in green, and similar
expression is indicated in black, as generated by Cluster 3.0. b. IHC of proteins related to normal renal function (KNG1, AQP2, SCNN1B). c. Immune
function (TLR2, CXCR4). d. Metabolic function (ENO2, CYP2J2,ALDOB). This pattern of expression is in accord with the microarray findings. Sum scores
are shown with n as indicated. *p,0.01 when comparing ccRCC to normal match.
doi:10.1371/journal.pone.0010696.g002
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PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10696Figure 3. Loss of developmental transcription factors in clear cell renal cell carcinoma. a. A microarray heatmap showing significant
downregulation of four developmental transcriptional factors in ccRCC and a table showing fold changes of DTFs and their known renal
developmental function. b. IHC validation of decreased expression of TFAP2B, DMRT2, and TFCP2L1. Sum scores are shown with n, as indicated.
*p,0.01 when comparing ccRCC to normal match. c. Microarray heatmap showing downregulation of TFCP2L1 and its regulated genes in ccRCC. S–
Stage, N–normal, T–tumor. Upregulation of genes is indicated in red, downregulation is indicated in green, and similar expression is indicated in
yellow, as generated by Genetree.
doi:10.1371/journal.pone.0010696.g003
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genes from our ccRCC data set that represented an EMT genotype
(Fig. 7a). Well known upregulated molecular markers include N-
cadherin (CDH2, M34064), fibronectin (FN1, AK026737), trans-
forming growth factor b1( T G F b1, BC000125) and vimentin (VIM,
A1922599) (Fig. 7a). We validated vimentin (VIM) and N-cadherin
(CDH2) at the protein level (Fig. 7b).Vimentinprotein expression in
ccRCC has been previously described by us and others [25,26]. Our
results agree with previously reported findings that reveal upregulated
expression of fibronectin in ccRCC at the gene and protein levels
[11,27,28]. In summary, the pattern of directional alterations in our
gene set indicates for an EMT gene expression signature and is
consistent with an EMT phenotype. We further validated our
findings by comparing a publicly available gene expression database
(GSE#15641) of early-stage ccRCC against normal renal samples
(Fig. S3).
Cellular differentiation model in pathogenesis of ccRCC
Based on our cumulative data, we propose a model for aberrant
cellular differentiation events in renal carcinogenesis that includes
Figure 4. Adipogenic differentiation signature in clear cell renal cell carcinoma. a. Heatmap showing adipogenic gene expression
signature in ccRCC. Upregulation of genes is indicated in red, downregulation is indicated in green, and similar expression is indicated in black. b. IHC
showing lipid-laden clear cell morphology of ccRCC, increased expression of ADFP, and decreased expression of GATA2 in ccRCC. Sum scores are
shown with n, as indicated. *p,0.01 when comparing ccRCC to normal match.
doi:10.1371/journal.pone.0010696.g004
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EMT and adipogenic transdifferentiation, which leads to ccRCC
(Fig. 8).
Discussion
Our study links biological pathways in ccRCC using gene array
and pathway analyses of patient-matched normal renal and ccRCC
tissues. Furthermore, we have validated a number of genes that are
altered in ccRCC that were previously undefined. The ccRCC
pathway signature is largely characterized by three major biological
alterations: 1) Lossof renalfunction that is reflectedby down-regulation
of pathways related to normal renal function, such as excretion and
electrolyte and ion channels. It is likely linked to a loss of renal
epithelial differentiation since the pathway-related renal functions
are performed by renal epithelial cells. 2) Down-regulation of various
metabolic pathways, which indicates a significant metabolic alteration
in ccRCC compared to normal renal cells. The metabolic pathways
at the top of our pathway list include butanoate, propanoate, and
valine, leucine and isoleucine degradation. These were also down-
regulated in another study [29], in which analysis of ccRCC was
performed using proteomics and metabolic profile. These pathways
are also down-regulated in metastatic colon cancer [30]. Some of
these metabolic changes are likely related to VHL gene mutation
and/or the Warburg effect [31,32]. 3) The activation of immune
pathways, especially antigen presenting and processing pathways, is
quitestriking.Thesame finding isseenwhen ccRCCiscomparedto
papillary RCC (data not shown). In addition, an overexpression of
immune genes has been previously reported [33]. This immune
gene expression signal is likely coming from tumor infiltrating
immune cells; however, aberrant immune gene expression by
ccRCC cells is also contributory, shown by our elevated TLR2 and
CXCR4 expression data. Increased expression of both of these
proteins has been linked to progressive renal disease and tumor
formation/angiogenesis [34];[35];[36]. It is common for ccRCC to
contain areas of necrosis, especially when the tumor grows faster
Figure 5. Adipogenic differentation in clear cell renal cell carcinoma. a. Cellular differentiation experiments showing that KIJ-308 and KIJ-
265 ccRCC cells are capable of adipogenic differentiation and become lipid-laden in adipogenic media, as indicated by Oil Red ‘O’ staining. Normal
patient-matched cells were unable to differentiate. b. A498 ccRCC cells are also capable of adipogenic differentiation, as indicated by Oil Red ‘O’
staining, unlike normal renal canine MDCK cells. c. Under adipogenic media conditions, ccRCC also produces glycogen, as shown by a PASH stain.
doi:10.1371/journal.pone.0010696.g005
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10696Figure 6. Osteogenic differentation in clear cell renal cell carcinoma. a. Cellular differentiation experiments showing that KIJ-308 and KIJ-
265 ccRCC cells are capable of osteogenic differentiation in osteogenic media by developing calcium deposits, as shown by Alizarin Red stain. Normal
patient-matched cells were unable to differentiate. b. A498 ccRCC cells are also capable of osteogenic differentiation, as shown by Alizarin Red stain,
unlike normal renal canine MDCK cells.
doi:10.1371/journal.pone.0010696.g006
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a number of damage-associated molecular patterns (DAMPs) that
are generated in the wake of cell death [37];[38];[39].
TLR2:DAMP interactions are important in the generation and
maintenance of chronic inflammation that is integral to the disease
process. Similarly, the homeostatic chemokine stromal cell-derived
factor-1 (CXCL12/SDF-1) regulates many vital biological process-
es, including neovascularization and tumorigenesis via binding to
the widely expressed receptor CXCR4 [40]. CXCR4-expressing
tumor cells preferentially metastasize to tissues that highly express
CXCL12, including the lung, liver, LN, and bone marrow
[41];[42]. Interestingly, CXCR4 expression within a tumor
increases, through HIF-1a, as the oxygen concentration decreases;
this action enhances the metastatic potential of the tumor cells [43].
Consequently, there is a great deal of interest in developing anti-
cancer therapeutics targeting CXCR4 [44]; [45]. It has been
previously shown that other immune genes such as TLR3 [46] and
B7-H1 ligand [47], are aberrantly expressed in ccRCC cells. The
activated immune state may be linked to the responsiveness of
ccRCCto immunotherapies,which makesccRCConeofonlya few
cancers that responds to immune therapies [48]; [49].
Our data indicate that ccRCC has undergone EMT with an
acquisition of mesenchymal/adipogenic differentiation signature
and a loss of epithelial differentiation. Our work confirms a recent
Figure 7. Epithelial mesenchymal transition in ccRCC. a. A heatmap showing the increased expression of some markers associated with EMT.
Upregulation of genes is indicated in red, downregulation is indicated in green, and similar expression is indicated in black. b. IHC validation of two
known markers of EMT: vimentin and N-cadherin. Sum scores are shown with n, as indicated. *p,0.01 when comparing ccRCC to normal match.
doi:10.1371/journal.pone.0010696.g007
Figure 8. Proposed model for cellular differentiation in ccRCC.
During normal renal development, mesenchymal stem cells undergo
mesenchymal epithelial transition (MET) to develop into normal renal
epithelial cells (NREs). In renal carcinogenesis, NREs undergo de-
differentiation and epithelial mesenchymal transition (EMT), followed by
adipogenic differentiation to develop into ccRCC.
doi:10.1371/journal.pone.0010696.g008
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wound-healing signature in ccRCC that the authors associated
with EMT [50]. The authors concluded that concomitant loss of
differentiation and acquisition of a wound-healing signature was
associated with EMT. Moreover, this signature was highly
prognostic for poor survival.
We have revealed a gene expression signature and IHC findings
that are consistent with adipogenesis in ccRCC. Moreover, our
differentiation experiments have validated that ccRCC cells can
undergo adipogenic transdifferentiation. It is well known that clear
cell morphology is quickly lost when ccRCC cells are grown in
standard cell culture media. In adipogenic media, ccRCC cells
become adipogenic and redevelop clear cell morphology accumu-
lating lipids, recapitulating the in vivo phenotype. It is interesting
that in vitro adipogenic differentiation also leads to glycogen
accumulation, which is another biological event responsible for
clear cell morphology. These findings indicate that the clear cell
morphology is a phenotypic marker of EMT, since adipogenic
differentiation is a mesenchymal event.
Our in vitro differentiation experiments reveal a pluripotent
mesenchymal stem cell-like quality in ccRCC cells with the
capacity to undergo adipogenic and osteogenic transdifferentia-
tion. This stem cell-like quality belongs to the tumor cell
population but not to the patient-matched normal renal epithelial
cell population. Previous studies show that cells induced to
undergo EMT can acquire stem cell-like qualities [51]. We believe
that the stem cell-like qualities observed in ccRCC are directly
linked to EMT. Because ccRCC cells are capable of pluripotent
differentiation in vitro and undergo adipogenic differentiation
preferentially in vivo in human patients, it is likely that the
adipogenic process is an important component of renal carcino-
genesis. It is also possible that preferential adipogenic differenti-
ation may be due to prevailing ecological factors in the kidney.
Heuristically, we think that cellular differentiation experiments
using differentiation media is useful for determining mesenchymal
stem cell-like qualities in cancer cells. In addition, the stem cell-like
characteristic of ccRCC may be responsible for its notorious drug
resistance [52]; [53]. Recently, active compounds, such as
Salinomycin, with cytotoxicity against stem cells were identified
and used in cells with induced EMT changes and stem cell-like
features [54].
Pathway and cellular differentiation changes in ccRCC may be
partly mediated by a loss of four developmental transcription
factors identified in our study. Since transcription factors typically
regulate multiple genes, dramatic attenuation of an expression of
four DTFs could have a major impact on biological function in
ccRCC. One of the DTFs, GATA3, may play a crucial role in
ccRCC, as it can potentially regulate all three biologic alterations
identified in ccRCC: loss of renal epithelial differentiation,
adipogenic differentiation, and immune activation. GATA3 is
important for renal development [55]; [56] and is necessary for
nephric duct morphogenesis in the pro/mesonephric kidney [57].
A novel mutation in the GATA3 gene that results in haplodefi-
ciency causes HDR syndrome (hypoparathyroidism, deafness,
renal dysplasia) [58]; [59]. GATA3 also inhibits adipogenesis [20];
[21] and regulates immune function [60]. Because TFCP2L1
controlled genes are down-regulated in ccRCC and it is known to
mediate renal epithelial cell development and tubule formation,
loss of TFCP2L1 may play an important role in epithelial de-
differentiation. TFAP2B is a member of the AP-2 family of
transcription factors that functions as both a transcriptional
activator and repressor. It appears to be required for proper
terminal differentiation and function of renal tubular epithelia [61]
and is integral to the survival of renal epithelial cells during renal
development [62]. DMRT2 is the top-ranking gene in our ccRCC
gene expression dataset with the highest discriminant power based
on our analysis using Fisher discriminant analysis (FDA) (Data not
shown). This transcription factor is important for myogenesis and
sex determination [63]. DMRT2 is also expressed in the
urogenital tract [64] and its mutations are associated with renal
abnormalities [65].
Based on our findings, we propose a model (Fig. 8) for aberrant
cellular differentiation in ccRCC. Developmentally, kidneys are
mesenchymal in origin and develop by biological processes, which
includes mesenchymal epithelial transition (MET) [66]. We
believe this process is reversed in ccRCC, which results in EMT
and dedifferentiation. In our model, normal renal epithelial cells
experience dedifferentiation and EMT as well as preferential
adipogenic differentiation to develop an adipogenic phenotype in
ccRCC. As a result of EMT and dedifferentiation, we postulate
that ccRCC cells possess stem cell-like qualities. Since our samples
came from patients with early-stage ccRCC, it appears that EMT
plays a prominent role in renal carcinogenesis. This finding is in
line with the important role of EMT pathogenesis of cancer [67].
Our present findings shed new light on the biology of ccRCC
and have implications for future research. We showed a
comprehensive pathway signature and identified an adipogenic
transdifferentiation signature in ccRCC. We revealed that clear
cell morphology is a marker of adipogenic transdifferentiation and
EMT. We identified four DTFs, which may play a role in ccRCC
due to loss of expression. Furthermore, our in vitro differentiation
experiments may be useful as an assay for determining the
pluropotency of cancer cells that have undergone EMT. With an
implication for cell models used in ccRCC research, we showed
that adipogenic media can restore the clear cell morphology in
ccRCC cell lines. Since these cells exhibit the characteristic
ccRCC phenotype, we suggest that they may be another relevant
in vitro model to study ccRCC.
Materials and Methods
This study was approved by the Mayo Institutional Review
Board Committee. The tissues used in this study were either de-
identified or were archival tissues and thus patient consent is not
necessary.
Study Samples
The tissue samples for the microarray study consisted of 10
patient-matched normal renal cortex and ccRCC tissues, five from
stage I and five from stage II ccRCC. Both early-stage I and II
tumors were localized disease; stage I tumors were less than 7 cm
and stage II tumors were greater than 7 cm. We saw little to no
difference in gene expression between the two tumor stages.
Validation by real time quantitative PCR (qPCR) was performed
using an independent set of 15 early-stage ccRCC patient-matched
normal and renal samples. Another independent set of patient
samples was used to measure protein levels by immunohistochem-
istry(IHC)intissuearrayscomprisedof50pairedearly-stageccRCC
patient-matched normal and renal samples for immunohistochem-
ical (IHC) validation. An n value was assigned for each IHC that
indicated scorable samples from the tissue arrays. Rarely were all
array samples intact, which allowed all 50 samples to be read. The
pathologic diagnosis was confirmed by a central pathology review
and was approved by the institutional review board.
Microarray Protocols
DNA microarray experiments were performed using the
Affymetrix HG-U133 set, which consisted of HG-U133a and
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accordance with standard protocols. The U-133 set included
almost 45,000 probe sets, which included approximately 33,000
well-substantiated human genes. The background correction,
probe summarization, and data normalization was performed
with the GCOS 1.2 (Affymetrix, Santa Clara, CA) that used
Affymetrix default analysis settings and global scaling as a
normalizing method. Gene expression data from the two chips
were combined with a scaling methodology. The gene expression
data and the details of the data processing and methodology were
deposited at Gene Expression Omnibus (Accession#GSE-6344).
To combine HG-U133 set A and B chip data we used the 100
normalizing probe sets, which scaled the set B to set A and created
a combo chip with 44760 probe sets. After the combo chip was
made we used ‘‘trimmed mean’’ to scale the chips and filter out the
genes with detection call ‘‘Absent in ALL’’ the chips and absolute
fold change less than 2 in all of the possible pairwise comparisons.
This resulted in 27,763 probe sets. We performed ANOVA on this
probe set to determine statistical significance. Probes with p-
value,0.05 totaled 13,729 genes. We used this gene set for our
final analysis.
Bioinformatics methods
Pathway analysis. Pathway analysis using the SigPathway
package has been described elsewhere [68]. The SigPathway
package [8] version 1.1.3 is available as a Bioconductor package
(http://www.bioconductor.org) and employs two statistical
parameters (NTK and NEK) to rank the pathways. NTK is a
measure of the degree that a given pathway differs from the other
pathways. NEK is a measure of the degree that the pathway
composite expression differs between phenotypes. Pathways were
ranked according to the average of the rank-orders of NTK and
NEK; false discovery rate (q value) was calculated to adjust for
multiple testing. The rank must be high in both rank-orders to
minimize false positives.
Cluster analysis. Cluster 3.0 [69] was used to perform
hierarchical cluster analyses using uncentered correlation and
average linkage. Cluster analyses were performed on the most
differentially expressed genes that were related to three pathway
categories: 1) greater than two-fold difference for renal function-
related genes (Fig. 1a), 2) greater than seven-fold difference for
metabolic genes (Fig. 1b) and 3) greater than four-fold difference
for immune genes (Fig. 1c); the statistical cutoff was P,0.05.
Hierarchical cluster analyses were also performed on real time
qPCR data on validated genes (Fig. 2a), adipogenesis genes
(Fig. 4a), and EMT genes (Fig. 7a). Genetree methodology in
GeneSpring (version 7.3, Agilent Technologies, Santa Clara, CA)
was applied for cluster analysis that used Pearson correlation and
average linkage on four DTFs (Fig. 3a), TFCP2L1, and its
regulated genes (Fig. 3c). Fold changes and statistical significance
of genes by analysis of variance (ANOVA) were performed in
GeneSpring (version 7.3, Agilent Technologies, Santa Clara, CA).
Multiple testing correction was done by the Benjamini and
Hochberg method.
We analyzed an independent ccRCC gene expression database
(GSE#15641) which was deposited at Gene Expression Omnibus
(GEO) to validate our adipogenic and EMT signatures. The data
was generated using gene array HG-U133A and preprocessed
using MAS5 (Affymetrix, Santa Clara, Ca). We analyzed stage 1
and 2 ccRCC (n=13) and normal samples (n=23). Heatmaps
were derived using our adipogenic and EMT signature gene lists
(Fig. S2 and S3) through hierarchical clustering with uncentered
correlation metric and average linkage method (Cluster 3.0).
RNA isolation and quantitative PCR
Real time PCR (qPCR) was used to measure the changes in the
mRNA levels of multiple genes from three different pathway
categories in patient-matched renal samples. Total mRNA was
isolated from tissue using Totally RNA (Ambion, Austin, TX), per
the manufacturer’s protocol, followed by ethanol precipitation and
Chromaspin column. The O.D. 260/280 ratio of the mRNA was
at least 1.8 and the 18S/28S bands were verified on a 1% agarose
gel. The RT step was achieved by synthesizing cDNA from 3 mg
RNA using the High Capacity Reverse Transcription kit as per the
manufacturer’s protocol (Applied Biosystems Foster City, CA).
Applied Biosystems’ assays-on-demand assay mix of primers and
TaqManH MGB probes (FAM
TM dye-labeled) for the genes listed
in Table S1 were used for qPCR in a high throughput TILDA
platform. Data were normalized to POLR2A for each sample and
DCT values were calculated in matched normal and tumor
patients. Samples were also normalized to UBC and KPNA6 for
verification. Data were presented as a heatmap using cluster 3.0:
uncentered correlation and incomplete linkage were used
(Fig. 2a).
Immunohistochemistry
IHC was performed on patient-matched renal samples to
validate genes from three pathway categories at the protein level.
Renal tissues were mounted on slides either from paraffin-
embedded blocks for IHC or from frozen sections for Oil Red
‘O’ staining (Sigma-Aldrich, St. Louis, MO), per the manufactur-
er’s protocol. Samples were blocked with Diluent that contained
Background Reducing Components (Dakocytomation, Denmark)
for 30 minutes and probed for specified antibodies that included:
KNG1, AQP2, TFAP2B, ENO2 (Santa Cruz, Santa Cruz, CA),
SCNN1B, TLR2, GATA2 (Novus, Littleton, CO), CXCR4 (BD
Pharmingen, San Diego, CA), CYP2J2, ALDOB (Abcam, Cam-
bridge, MA), DMRT2, TFCP2L1 (Lifespan Biosciences, Seattle,
WA), Vimentin (Sigma-Aldrich), and ADFP (Acris Antibodies,
Germany). Negative sections were prepared by incubating the
slides in the absence of the primary antibody. The staining of the
tissue sections was scored and verified by a pathologist (KW) based
upon signal intensity (0-3+) and the percentage of positive cells
(0#5%, 1+=5-20%, 2+=20-50%, and 3+$50%). Cases were
excluded from the study if a section could not be assigned a score
due to insufficient tumor tissue. Afterwards, the grading score was
summed and reported as summed scores followed by Chi-square
analysis (df=3, p,0.01). Images were obtained at 20X using
Scanscope XT and Imagescope software (Aperio Technologies,
Vista, CA).
Cell culture and differentiation experiments
The human A498 ccRCC cell line and MDCK canine normal
renal cells were purchased from ATCC (Manassas, VA) while KIJ-
265 (Stage 4) and KIJ-308 (Stage 2) cell lines and primary cells
were established in the Copland laboratory and derived from
human renal clear cell carcinoma and normal-matched tissues.
Renal cells were maintained in complete renal media containing
MEM (Cellgro Herndon, VA) supplemented with 10% fetal
bovine serum (Hyclone Logan, UT), 1 mM sodium pyruvate,
10 mM HEPES, 1% non-essential amino acids and penicillin-
streptomycin-amphotericin B (Cellgro Herndon, VA) at 37uCi na
humidified atmosphere with 5% CO2. For differentiation
experiments, cells were maintained for 2 weeks in complete renal
media, adipogenic, or osteogenic media. For adipogenic differen-
tiation, media was supplemented for 2 weeks with 0.1 mM
dexamethasone, 10 mg/mL insulin, 100 mM indomethacin, and
500 mM isobutylmethylxanthine (Sigma-Aldrich, St. Louis, MO)
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protocol (Richard Allan Scientific, Kalamazoo, MI). For osteo-
genic differentiation, media was supplemented for 2 weeks with
50 mM Ascorbic acid, 0.1 mM Dexamethasone, and 10 nM beta-
Glycerolphosphate (Sigma-Aldrich, St. Louis, MO) and staining
with Alizarin Red S, per the manufacturer’s protocol (Sigma-
Aldrich, St. Louis, MO).
Supporting Information
Table S1 Table of primers used in TILDA qPCR. KPNA6,
POLR2A and UBC were used as internal controls.
Found at: doi:10.1371/journal.pone.0010696.s001 (0.06 MB
DOC)
Figure S1 Renal developmental genes are down-regulated in
ccRCC. The large heatmap shows differential expression of
transcription factors between ccRCC and normal renal samples.
The smaller heatmap highlights clustering of down-regulated renal
developmental transcription factors (GATA3, TFAP2B, DMRT2,
and TFCP2L1) in a subcluster. Upregulation of genes is indicated
in red, downregulation is indicated in green, and a similar
expression is indicated in black, as generated by Cluster 3.0.
Found at: doi:10.1371/journal.pone.0010696.s002 (0.69 MB TIF)
Figure S2 An adipogenic gene expression signature of ccRCC is
elucidated. Normal denotes normal renal samples. Gene expres-
sion data are from a publicly available database, GSE#15641,
deposited at Gene Expression Omnibus (GEO). Details on the
clustering method are mentioned in the text. Red color indicates
an upregulation of genes, green indicates a downregulation, and
black indicates a similar expression.
Found at: doi:10.1371/journal.pone.0010696.s003 (0.49 MB TIF)
Figure S3 An epithelial mesenchymal transition (EMT) gene
expression signature of ccRCC is identified. Normal denotes
normal renal samples. Gene expression data are from a publicly
available database, GSE#15641, deposited at Gene Expression
Omnibus (GEO). Details on the clustering method are mentioned
in the text. Red color indicates an upregulation of genes, green
indicates a downregulation, and black indicates a similar
expression.
Found at: doi:10.1371/journal.pone.0010696.s004 (0.66 MB TIF)
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